Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma

NCT03636256 is registered in ClinicalTrials.gov with NanOlogy, LLC as lead sponsor.

NCT NCT03636256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03636256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma
Lead sponsor
NanOlogy, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
April 2, 2019
Completion date
November 2, 2021
Enrollment
36 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cancer of the bladder, malignant tumor of the urinary bladder, urinary bladder cancer, urinary bladder neoplasm, urogenital neoplasms, urologic cancer, urologic neoplasms, urothelial carcinoma